Fig. 4

The antitumor effects of FAST in three tumor models of mice. a‒f The in vivo antitumor effects of FAST in the colon cancer model of mice. The model was constructed by subcutaneously injecting the CT26 cells (n = 10 mice). a Schematics of animal treatment. s.c. subcutaneous injection; i.v., intravenous injection. b Average body weight. c Tumor growth curve. d Tumor imaging. e Tumor weight. Data are shown as mean ± s.d (n = 10 mice). f Kaplan-Meier survival curve (n = 10 mice). The statistical significance was analyzed by the log-rank test. g‒l The in vivo antitumor effects of FAST in the pulmonary metastatic melanoma model. The model was constructed by intravenously injecting the B16F10 cells. g Schematics of animal treatment. h Lung imaging. i Quantified B16F10 lung metastatic-like tumor foci. Data are shown as mean ± s.d (n = 9 mice). j H&E-stained lung section imaging. k Tumor area as a percent of total lung area. Data are shown as mean ± s.d (n = 9 mice). l Kaplan-Meier survival curve (n = 10 mice). The statistical significance was analyzed by the log-rank test. (M‒Q) The in vivo antitumor effects of FAST in spontaneous breast cancer model (n = 5 mice). m Schematics of animal treatment. n Representative image showing gross appearance of tumors. Dotted-line circles demarcate palpable mammary tumor nodules. o Comparison of the number of palpable tumor nodules. p Comparison of total tumor burden. Tumor burden was calculated by summating the volume of every tumor nodule per mouse. Data are presented as mean ± s.d. (n = 5 mice). q Kaplan-Meier survival curve. The statistical significance was analyzed by the log-rank test